Proprietary AI analyst is now available

Cathay Biotech Valuation Multiples

Discover Cathay Biotech's revenue and EBITDA valuation multiples and investment history, alongside public comparables like UPL, Sumitomo Chemical, Wacker Chemie, Celanese and more.

Cathay Biotech Overview

About Cathay Biotech

Cathay Biotech Inc is engaged in research, development, production, and sales of new bio-based materials. The company owns the TERRYL brand, which focuses on bio-based polyamide fibers for textiles, and ECOPENT, which serves the engineering materials market.


Founded

2000

HQ

China

Employees

1.7K

Financials (LTM)

Revenue: $512M
EBITDA: $134M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cathay Biotech Financials

Cathay Biotech reported last 12-month revenue of $512M and EBITDA of $134M.

In the same LTM period, Cathay Biotech generated $177M in gross profit, $134M in EBITDA, and $98M in net income.


Cathay Biotech P&L

In the most recent fiscal year, Cathay Biotech reported revenue of $485M and EBITDA of $141M.

Cathay Biotech is profitable as of last fiscal year, with gross margin of 34%, EBITDA margin of 29%, and net margin of 17%.

See analyst estimates for Cathay Biotech
LTMLast FY202320242025202620272028
Revenue$512M$485M$311M$436M$485M
Gross Profit$177M$166M$90M$136M$166M
Gross Margin35%34%29%31%34%
EBITDA$134M$141M$113M$132M$141M
EBITDA Margin26%29%36%30%29%
EBIT Margin22%20%13%16%20%
Net Profit$98M$83M$54M$72M$83M
Net Margin19%17%17%17%17%

Financial data powered by Morningstar, Inc.

Cathay Biotech Stock Performance

Cathay Biotech has current market cap of $5B, and enterprise value of $4B.


Cathay Biotech's stock price is $7.34.

Cathay Biotech has an EPS (earnings per share) of $0.11.

See more trading valuation data for Cathay Biotech
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$5B-0.7%---$0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cathay Biotech Valuation Multiples

Cathay Biotech trades at 8.0x EV/Revenue multiple, and 30.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Cathay Biotech

Cathay Biotech Financial Valuation Multiples

As of June 26, 2026, Cathay Biotech has market cap of $5B and EV of $4B.

Cathay Biotech has a P/E ratio of 54.0x.

LTMLast FY202320242025202620272028
EV/Revenue8.0x8.4x13.1x9.3x8.4x
EV/EBITDA30.3x29.0x36.0x30.8x29.0x
EV/EBIT36.6x41.0x101.1x56.8x41.0x
EV/Gross Profit22.9x24.5x45.4x29.9x24.5x
P/E54.0x64.1x98.1x73.5x64.1x
EV/FCF-(81.4x)(27.6x)n/m(81.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cathay Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cathay Biotech Margins & Growth Rates

Cathay Biotech grew revenue by 12% and EBITDA by 7% in the last fiscal year.

In the most recent fiscal year, Cathay Biotech reported gross margin of 34%, EBITDA margin of 29%, and net margin of 17%.

See estimated margins and future growth rates for Cathay Biotech

Cathay Biotech Margins

Last FY202420252026202720282029
Gross Margin34%31%34%35%
EBITDA Margin29%30%29%28%
EBIT Margin20%16%20%24%
Net Margin17%17%17%21%
FCF Margin(10%)(1%)(10%)-

Cathay Biotech Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%40%11%12%
Gross Profit Growth15%52%22%15%
EBITDA Growth7%17%6%7%
EBIT Growth32%78%39%32%
Net Profit Growth39%33%15%39%
FCF Growth-(98%)1416%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Cathay Biotech Operational KPIs

Cathay Biotech's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.

Cathay Biotech's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cathay Biotech's Rule of X is 58% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Cathay Biotech
LTMLast FY202320242025202620272028
Rule of 4041%40%---
Bessemer Rule of X63%58%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.0M---
S&M Expenses to Revenue2%2%1%1%1%
G&A Expenses to Revenue5%5%3%2%2%
R&D Expenses to Revenue-7%9%8%7%
Opex to Revenue-14%16%15%14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cathay Biotech Competitors

Cathay Biotech competitors include UPL, Sumitomo Chemical, Wacker Chemie, Celanese, Fuchs, Sensient Technologies, Balchem, Xin Feng Ming Group, IMCD and USA Rare Earth.

Most Cathay Biotech public comparables operate across Advanced Materials, Chemicals, Bioindustrials, DeepTech, BioTech and AgriTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
UPL1.3x1.3x6.7x6.7x
Sumitomo Chemical0.7x0.7x5.8x6.2x
Wacker Chemie1.0x1.0x12.6x10.1x
Celanese1.7x1.7x8.7x8.2x
Fuchs1.3x1.3x8.9x8.8x
Sensient Technologies3.7x3.5x20.2x18.9x
Balchem5.3x5.2x20.2x19.3x
Xin Feng Ming Group0.8x0.8x11.1x9.2x

This data is available for Pro users. Sign up to see all Cathay Biotech competitors and their valuation data.

Start Free Trial

Cathay Biotech VC Funding History

Before going public, Cathay Biotech raised $10M in total equity funding, across 1 round.


Cathay Biotech Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-19Series BHBM Healthcare Investments$10M--

Investments by Cathay Biotech

Cathay Biotech has invested in 1 company to date.

Latest investment by Cathay Biotech was on June 16th 2026. Cathay Biotech invested in MoleculeMind in their $86M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Cathay Biotech

MoleculeMind
MoleculeMind
Description
MoleculeMind is a Hangzhou-based AI platform for de novo protein design. The system employs generative models to engineer novel enzymes and therapeutic proteins, optimizing sequences for stability and function. Applications span antibody engineering, vaccine antigens, and industrial biocatalysts, accelerating discovery cycles for biotech firms targeting metabolic disorders and crop protection agents.
MoleculeMind is a Hangzhou-based AI platform for de novo protein design. The system employs generative models to engineer novel enzymes and therapeutic proteins, optimizing sequences for stability and function. Applications span antibody engineering, vaccine antigens, and industrial biocatalysts, accelerating discovery cycles for biotech firms targeting metabolic disorders and crop protection agents.
HQ CountryChinaChina
HQ City
Beijing
Beijing
Deal Date16 Jun 202620 Feb 2023
RoundSeries ASeed
Raised$86M$15M
InvestorsOriental Fortune Capital; Cathay Biotech; Infinity Equity; Caixin Capital; Core Air Capital; Suzhou Sepax Technologies; Guofang Venture Capital; Pudong Chuangtou; COFCO; Blue Bridge Capital; Fosun Capital; Zhong Xin Hang Capital Management; Eastern Bell CapitalCathay Biotech; Lenovo Capital and Incubator Group (LCIG); HSG
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Cathay Biotech investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cathay Biotech

When was Cathay Biotech founded?Cathay Biotech was founded in 2000.
Where is Cathay Biotech headquartered?Cathay Biotech is headquartered in China.
How many employees does Cathay Biotech have?As of today, Cathay Biotech has over 1K employees.
Is Cathay Biotech publicly listed?Yes, Cathay Biotech is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Cathay Biotech?Cathay Biotech trades under 688065 ticker.
When did Cathay Biotech go public?Cathay Biotech went public in 2020.
Who are competitors of Cathay Biotech?Cathay Biotech main competitors include UPL, Sumitomo Chemical, Wacker Chemie, Celanese, Fuchs, Sensient Technologies, Balchem, Xin Feng Ming Group, IMCD, USA Rare Earth.
What is the current market cap of Cathay Biotech?Cathay Biotech's current market cap is $5B.
What is the current revenue of Cathay Biotech?Cathay Biotech's last 12 months revenue is $512M.
What is the current revenue growth of Cathay Biotech?Cathay Biotech revenue growth (NTM/LTM) is 15%.
What is the current EV/Revenue multiple of Cathay Biotech?Current revenue multiple of Cathay Biotech is 8.0x.
What is the current EBITDA of Cathay Biotech?Cathay Biotech's last 12 months EBITDA is $134M.
What is Cathay Biotech's EBITDA margin?Cathay Biotech's last 12 months EBITDA margin is 26%.
What is the current EV/EBITDA multiple of Cathay Biotech?Current EBITDA multiple of Cathay Biotech is 30.3x.
How many companies Cathay Biotech has acquired to date?Cathay Biotech hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Cathay Biotech has invested to date?As of June 2026, Cathay Biotech has invested in 1 company.
What was the last Cathay Biotech investment?On 16th June 2026 Cathay Biotech invested in MoleculeMind, participating in a $86M Series A round, alongside Oriental Fortune Capital, Infinity Equity, Caixin Capital, Core Air Capital, Suzhou Sepax Technologies, Guofang Venture Capital, Pudong Chuangtou, COFCO, Blue Bridge Capital, Fosun Capital, and 2 other investors.
In what companies Cathay Biotech invested in?Cathay Biotech invested in MoleculeMind.

See public comps similar to Cathay Biotech

Lists including Cathay Biotech

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial